AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19513794 — intervention group
Group type: EXPERIMENTAL
Intervention: Local cold stress (Group 2)
Number of subjects: 22
Study 19513794 — intervention group
Group type: COMPARATOR
Intervention: Control (t=0)
Number of subjects: 22
Study 18762495 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-modification program designed to improve infant sleep (n = 174) delivered by well-child nurses at ages 8 to 10 months
Number of subjects: 328
Study 18762495 — intervention group
Group type: COMPARATOR
Intervention: Usual well-child care (n = 154)
Number of subjects: 328
Study 18762495 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-modification program designed to improve infant sleep (n = 174)
Number of subjects: 328
Study 15975302 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao granule (YXQNG)
Number of subjects: 83
Study 15975302 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine (ND)
Number of subjects: 83
Study 12952839 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg per day
Number of subjects: 354
Study 12952839 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg per day
Number of subjects: 354
Study 12952839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 10023697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 7 days
Number of subjects: 41
Study 10023697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 3 days
Number of subjects: 41
Study 10023697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 5 days
Number of subjects: 41
Study 10023697 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at 500 mg/body/day for 10 days
Number of subjects: 41
Study 8683517 — intervention group
Group type: EXPERIMENTAL
Intervention: Hackett's AMS score
Number of subjects: 99
Study 8683517 — intervention group
Group type: EXPERIMENTAL
Intervention: Lake Louise AMS score
Number of subjects: 99
Study 8683517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Number of subjects: 99
Study 1496150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission self-instruction
Number of subjects: 50
Study 1496150 — intervention group
Group type: COMPARATOR
Intervention: Posthospital admission instruction of therapeutic exercises
Number of subjects: 50
Study 6541929 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxazolam with 0.55 g/kg alcohol
Number of subjects: 122
Study 6541929 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oxazolam with 0.55 g/kg alcohol
Number of subjects: 122
Study 6541929 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxazolam with 0.83 g/kg alcohol
Number of subjects: 122
Study 6541929 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.55 g/kg alcohol
Number of subjects: 122
Study 6541929 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 0.83 g/kg alcohol
Number of subjects: 122
Study 6541929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30835629 — intervention group
Group type: EXPERIMENTAL
Intervention: FertiQOL score
Number of subjects: 708
Study 30835629 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (PHQ-9 score of 5 or greater)
Number of subjects: 708
Study 30835629 — intervention group
Group type: COMPARATOR
Intervention: Low total testosterone
Number of subjects: 708
Study 30835629 — intervention group
Group type: COMPARATOR
Intervention: Erectile dysfunction
Number of subjects: 708
Study 30126766 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner in Sight (ESM self-monitoring and personalized feedback)
Number of subjects: 76
Study 30126766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-intervention (ESM self-monitoring without feedback)
Number of subjects: 76
Study 30126766 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 76
Study 27449412 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSB-5 600 mg, bid for 12 weeks
Number of subjects: 220
Study 27449412 — intervention group
Group type: COMPARATOR
Intervention: Placebo, bid for 12 weeks
Number of subjects: 220
Study 25299668 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1,200 mg) and cholecalciferol [2,000-6,000 IU] for 6 months
Number of subjects: 95
Study 25299668 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos for 6 months
Number of subjects: 95
Study 22482863 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-guided pre-emptive therapy (group 3, n = 71)
Number of subjects: 560
Study 22482863 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group 2, n = 142)
Number of subjects: 560
Study 20360754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cold exposure (16 degrees C) for 48 hours after 36 hours at neutral temperature (22 degrees C)
Number of subjects: 20
Study 20360754 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cold exposure (16 degrees C) for 48 hours
Number of subjects: 20
Study 18294477 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy plus pacemaker implantation and β-blocker therapy
Number of subjects: 1124
Study 18294477 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (no β-blockers)
Number of subjects: 1124
Study 15949431 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA plus PEI (group B)
Number of subjects: 150
Study 15949431 — intervention group
Group type: COMPARATOR
Intervention: RFA alone (group A)
Number of subjects: 150
Study 11986264 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) treatment for non-consecutive periods of 2 months and 1 month
Number of subjects: 28
Study 11986264 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) treatment
Number of subjects: 28
Study 10569659 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐sotalol (160 to 320 mg/day)
Number of subjects: 121
Study 10569659 — intervention group
Group type: COMPARATOR
Intervention: quinidine sulfate (600 to 800 mg/day)
Number of subjects: 121
Study 10569659 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐sotalol (for recent-onset AF)
Number of subjects: 121
Study 10569659 — intervention group
Group type: COMPARATOR
Intervention: quinidine sulfate (for recent-onset AF)
Number of subjects: 121
Study 10569659 — intervention group
Group type: COMPARATOR
Intervention: quinidine sulfate (for chronic AF)
Number of subjects: 121
Study 10569659 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐sotalol (for chronic AF)
Number of subjects: 121
Study 10569659 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐sotalol
Number of subjects: 121
Study 10569659 — intervention group
Group type: COMPARATOR
Intervention: quinidine sulfate
Number of subjects: 121
Study 8669516 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic shoes prescribed by clinicians specializing in foot care
Number of subjects: 0
Study 8669516 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1861917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfisoxazole 75 mg/kg per day for 6 months
Number of subjects: 125
Study 1861917 — intervention group
Group type: COMPARATOR
Intervention: Bilateral insertion of ventilation tubes (VTs)
Number of subjects: 125
Study 7103524 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate therapy
Number of subjects: 21
Study 30192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection
Number of subjects: 592
Study 30192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 592
Study 30192324 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 592
Study 30192324 — intervention group
Group type: COMPARATOR
Intervention: Open colonic resection
Number of subjects: 592
Study 26765633 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g·d of DHA
Number of subjects: 81
Study 26765633 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g·d of DHA
Number of subjects: 81
Study 26765633 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g·d of DHA
Number of subjects: 81
Study 26765633 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (irrespective of dose)
Number of subjects: 81
Study 26765633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 23937408 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 37
Study 23937408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gum chewing)
Number of subjects: 37
Study 23772853 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 2-12 mg
Number of subjects: 1109
Study 23772853 — intervention group
Group type: COMPARATOR
Intervention: Concomitant EIAEDs (carbamazepine, oxcarbazepine, phenytoin)
Number of subjects: 1109
Study 20439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-boosted protease inhibitor combinations
Number of subjects: 48
Study 20439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cleavage site substitutions at positions 128 (p17/p24) and 449 (p1/p6(gag))
Number of subjects: 48
Study 20439606 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cleavage site mutation at position 437 (TFP/p6(pol))
Number of subjects: 48
Study 17069817 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (workplace 'toolbox')
Number of subjects: 2
Study 17069817 — intervention group
Group type: COMPARATOR
Intervention: Reference organisation (no toolbox introduced)
Number of subjects: 2
Study 16240737 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 12899549 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with hook‐pins (n=36)
Number of subjects: 68
Study 12899549 — intervention group
Group type: COMPARATOR
Intervention: Primary arthroplasty (total or hemiarthroplasty) (n=32)
Number of subjects: 68
Study 12899549 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation
Number of subjects: 68
Study 12899549 — intervention group
Group type: COMPARATOR
Intervention: Primary arthroplasty
Number of subjects: 68
Study 10596413 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dose treatment with surfactant (Curosurf)
Number of subjects: 31
Study 10596413 — intervention group
Group type: COMPARATOR
Intervention: Single dose treatment with surfactant (Curosurf)
Number of subjects: 31
Study 8706486 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane-based anesthetic
Number of subjects: 15
Study 8706486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-based anesthetic
Number of subjects: 15
Study 8706486 — intervention group
Group type: COMPARATOR
Intervention: Both anesthetic groups pooled
Number of subjects: 15
Study 1877512 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of 8.7 mumol (2500 microgram) vitamin A and 46 mumol (20 mg) vitamin E
Number of subjects: 15419
Study 1877512 — intervention group
Group type: COMPARATOR
Intervention: 46 mumol vitamin E (control)
Number of subjects: 15419
Study 6962738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette averaging .64 mg nicotine (P2)
Number of subjects: 22
Study 6962738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette averaging .38 mg nicotine (P3)
Number of subjects: 22
Study 6962738 — intervention group
Group type: COMPARATOR
Intervention: Control group switched to another brand within ± .1 mg of their usual brand (P2)
Number of subjects: 22
Study 6962738 — intervention group
Group type: COMPARATOR
Intervention: Control group switched to another brand within ± .1 mg of their usual brand (P3)
Number of subjects: 22
Study 31056892 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFF 1000 mg
Number of subjects: 256
Study 31056892 — intervention group
Group type: COMPARATOR
Intervention: MPFF 500 mg
Number of subjects: 256
Study 30400947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rye-based bread (RB + RS2)
Number of subjects: 38
Study 30400947 — intervention group
Group type: COMPARATOR
Intervention: White wheat flour bread (WWB)
Number of subjects: 38
Study 25809810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutritional guidance for couples with AD
Number of subjects: 40
Study 25809810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS)
Number of subjects: 40
Study 25809810 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings with protein-rich snacks
Number of subjects: 40
Study 24012456 — intervention group
Group type: EXPERIMENTAL
Intervention: < 3 CTC per 7.5 mL blood and KRAS wild-type tumors
Number of subjects: 158
Study 24012456 — intervention group
Group type: COMPARATOR
Intervention: ≥ 3 CTCs and KRAS mutated tumors
Number of subjects: 158
Study 21345850 — intervention group
Group type: EXPERIMENTAL
Intervention: More intense therapy (low-dose hydrochlorothiazide and low-dose felodipine)
Number of subjects: 9711
Study 21345850 — intervention group
Group type: COMPARATOR
Intervention: Less-intense therapy (low-dose hydrochlorothiazide and placebo)
Number of subjects: 9711
Study 19302238 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate restoration
Number of subjects: 49
Study 19302238 — intervention group
Group type: COMPARATOR
Intervention: Delayed restoration
Number of subjects: 49
Study 17984136 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial left atrial cryoablation
Number of subjects: 69
Study 17984136 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve surgery alone
Number of subjects: 69
Study 15042537 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 12 weeks
Number of subjects: 26
Study 15042537 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-protein diet)
Number of subjects: 26
Study 11682427 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% carbohydrate drink (CHO)
Number of subjects: 252
Study 11682427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 252
Study 11682427 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 252
Study 10211032 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 75 mg in 0.9% saline 60 ml
Number of subjects: 5
Study 10211032 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 75 mg in 0.9% saline 60 ml and epinephrine 5 micrograms/ml
Number of subjects: 5
Study 7889580 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-burst stimulation (DBS)
Number of subjects: 44
Study 7889580 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) stimulation
Number of subjects: 44
Study 7889580 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS
Number of subjects: 44
Study 7889580 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF
Number of subjects: 44
Study 2925731 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 140
Study 2925731 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 140
Study 604377 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 604377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30987986 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (3 days/week for 3 months)
Number of subjects: 60
Study 30987986 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 25827960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg/m(2)/day of oral hydrocortisone in three divided doses
Number of subjects: 17
Study 25827960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 24640651 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination gymnastics combined with magnetic therapy and iodine-bromine baths
Number of subjects: 80
Study 21570371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherapy mask
Number of subjects: 50
Study 21570371 — intervention group
Group type: COMPARATOR
Intervention: Standard dressings alone
Number of subjects: 50
Study 18971509 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-min bout of treadmill walking
Number of subjects: 69
Study 18971509 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise period
Number of subjects: 69
Study 16322489 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with a treatment window >6 hours
Number of subjects: 32
Study 16322489 — intervention group
Group type: COMPARATOR
Intervention: Trials with a treatment window <=6 hours
Number of subjects: 32
Study 16322489 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials conducted in 1 country
Number of subjects: 32
Study 16322489 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with maximum allowable time from stroke to study enrollment
Number of subjects: 32
Study 16322489 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of mild strokes
Number of subjects: 32
Study 14613518 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor 1 g, o.d.
Number of subjects: 100
Study 14613518 — intervention group
Group type: COMPARATOR
Intervention: Placebo o.d.
Number of subjects: 100
Study 10942489 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal fetal fibronectin measurements
Number of subjects: 13360
Study 8822290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) for 5 days at 30 mg/kg/day in 2 divided doses
Number of subjects: 719
Study 8822290 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CAE) for 10 days at 30 mg/kg/day in 2 divided doses
Number of subjects: 719
Study 8822290 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (AMX/CL) for 10 days at 40 mg/kg/day in 3 divided doses
Number of subjects: 719
Study 1464862 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 16
Study 1464862 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 16
Study 1464862 — intervention group
Group type: COMPARATOR
Intervention: Deflazacort vs Prednisone
Number of subjects: 16
Study 6523650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (antibiotic group)
Number of subjects: 65
Study 6523650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 65
Study 6523650 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall infection rate
Number of subjects: 65
Study 31530586 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial context-enhancing functional training program
Number of subjects: 126
Study 31530586 — intervention group
Group type: COMPARATOR
Intervention: Functional training
Number of subjects: 126
Study 29084458 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Skills programme for young adult male offenders
Number of subjects: 96
Study 29084458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 96
Study 26881449 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality-targeted intervention
Number of subjects: 1210
Study 24567279 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole + lacosamide coadministration
Number of subjects: 36
Study 24567279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide + omeprazole coadministration
Number of subjects: 36
Study 24567279 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole alone
Number of subjects: 36
Study 24567279 — intervention group
Group type: COMPARATOR
Intervention: Lacosamide alone
Number of subjects: 36
Study 22508376 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa 450 mg/day
Number of subjects: 12
Study 22508376 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa 75 mg/day
Number of subjects: 12
Study 20224964 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐TOFHLA
Number of subjects: 1796
Study 20224964 — intervention group
Group type: EXPERIMENTAL
Intervention: REALM
Number of subjects: 1796
Study 17989600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 21
Study 17989600 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 21
Study 15899326 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11943520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation group (PaCO2 = 25‐35)
Number of subjects: 90
Study 11943520 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation group (PaCO2 = 35‐45)
Number of subjects: 90
Study 11943520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoventilation group (PaCO2 = 45‐55)
Number of subjects: 90
Study 9811379 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages consumed ad lib
Number of subjects: 30
Study 9811379 — intervention group
Group type: COMPARATOR
Intervention: Caffeine deprivation (abstained from caffeine)
Number of subjects: 30
Study 8929932 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity program (case management plus peer‐supervised housing)
Number of subjects: 0
Study 8929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium intensity group (peer‐supervised housing only)
Number of subjects: 0
Study 8929932 — intervention group
Group type: COMPARATOR
Intervention: Housed control group
Number of subjects: 0
Study 8929932 — intervention group
Group type: COMPARATOR
Intervention: Nonhoused control group
Number of subjects: 0
Study 8929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Program graduates
Number of subjects: 0
Study 8929932 — intervention group
Group type: EXPERIMENTAL
Intervention: Women in the study
Number of subjects: 0
Study 2163805 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m1099 (50 mg thrice daily)
Number of subjects: 12
Study 2163805 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar granules (5 g thrice daily)
Number of subjects: 12
Study 2163805 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY m1099
Number of subjects: 12
Study 2163805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BAY m1099 and Guar
Number of subjects: 12
Study 474948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine 0.4 mg
Number of subjects: 0
Study 474948 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 0
Study 30382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics during hospitalization until 8 weeks post-discharge
Number of subjects: 388
Study 30382002 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with probiotics
Number of subjects: 388